Syngene International has scheduled its 33rd Annual General Meeting (AGM) for Wednesday, July 29, 2026, at 3:30 PM IST via Video Conferencing. Shareholders will vote on a final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026. The record date to determine eligibility is Friday, June 26, 2026. The meeting will also consider the appointment of Mr. Siddharth Mittal as Managing Director and Chief Executive Officer for a five-year term effective July 01, 2026, with a proposed annual remuneration of ₹25 crore.

Key AGM Resolutions

The following table summarises the key resolutions to be considered at the 33rd AGM:

Leadership Transition and MD & CEO Remuneration

The Board recommends the appointment of Mr. Siddharth Mittal as Managing Director and Chief Executive Officer for a five-year term effective July 01, 2026. His proposed annual remuneration totals ₹25 crore, comprising fixed compensation of ₹10 crore, short-term incentives of ₹5 crore, and long-term incentives of ₹10 crore. Mr. Siddharth Mittal previously served as Managing Director and CEO of Biocon Limited, bringing over two decades of experience in strategic finance, M&A, and general management.

FY26 Financial Performance

Syngene reported consolidated revenue from operations of ₹37,387 Mn for FY26, up 3% year-on-year, with an Operating EBITDA margin of 25%. Profit after tax before exceptional items stood at ₹3,799 Mn. The company recognised exceptional items amounting to a net loss of ₹632 Mn, primarily relating to gratuity re-measurement following the notification of new Labour Codes and termination benefits extended to employees. After accounting for exceptional items, profit after tax for FY26 stood at ₹3,167 Mn. The company generated ₹5,207 Mn in net cash during the year and closed with a net cash position of approximately ₹18,003 Mn after funding capital expenditure.

The following table presents key standalone and consolidated financial metrics:

Subsidiary Performance

Syngene has three wholly owned subsidiaries. Syngene USA Inc. reported revenue of USD 12.25 million with a loss of USD 1.4 million. Syngene Scientific Solutions Limited generated total income of INR 4,255 million with a profit before tax of INR 287 million. Syngene Manufacturing Solutions Limited reported a total income of INR 0.6 million with a loss of INR 0.035 million and is yet to commence operations.

E-Voting and AGM Logistics

The company has appointed KFin Technologies Limited as the Registrar and Transfer Agent to facilitate e-voting and AGM proceedings. Remote e-voting will be open from Friday, July 24, 2026 (09:00 hours IST) to Tuesday, July 28, 2026 (17:00 hours IST). Shareholders must ensure their bank details and PAN are updated to receive dividend payments electronically and comply with Tax Deduction at Source (TDS) regulations. The AGM Notice and Annual Report for FY 2025-26 are available on the company's website at https://www.syngeneintl.com/investors/share-holder-services/ .

Syngene International has appointed Siddharth Mittal as its Managing Director and Chief Executive Officer, effective July 1, 2026. The leadership change marks a strategic transition for the global contract research, development, and manufacturing organization (CRDMO) as it aims to strengthen its commercial edge and operational excellence. Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on June 30, 2026.

Mittal brings nearly three decades of business leadership experience to the role. He joins Syngene International from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer. During his thirteen-year tenure at Biocon, he held the position of Chief Financial Officer before being appointed to the top leadership role. His tenure included securing key regulatory approvals and commercializing the GLP-1 portfolio across major international markets.

Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, expressed confidence in the new appointment. She stated that Syngene is at an inflection point and that Mittal's leadership, commercial acumen, and execution focus will help the company unlock its full potential. She highlighted his ability to lead businesses through periods of change and deliver sustainable growth.

Commenting on his new role, Siddharth Mittal said his immediate priority is to sharpen the company's commercial edge and strengthen delivery excellence. He emphasized combining scientific strengths with a focus on customer fulfilment and cost-competitiveness to restore growth momentum. Mittal aims to reinforce Syngene's standing as a global leader in CRDMO services.

Key Leadership Transition

The following table summarizes the key details of the leadership change at Syngene International: